CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer

Xuefeng Liu, Xiaomei Zhang, Qimin Zhan, Malcolm V Brock, James G. Herman, Mingzhou Guo

Research output: Contribution to journalArticle

Abstract

Aberrant promoter region hypermethylation of upstream transcription factors may be responsible for silencing entire anti-neoplastic gene networks. In this study, we explored whether transcription factor coding gene, caudal-related homeobox 2 (CDX2), is silenced by promoter hypermethylation in lung cancer, and examined its potential tumor-suppressive functions. Semi-quantitative RT-PCR showed that four of six lung cancer cell lines exhibited no or weak CDX2 expression. Expression of CDX2 was correlated to CDX2 promoter region methylation status, as determined by methylation-specific PCR (MSP) and bisulfite sequencing. Restoration of CDX2 expression was induced by treatment with demethylating drug 5-aza-2′-deoxycytidine (5-AZA) in lung cancer cell lines. Methylation of CDX2 was common in human primary lung cancer (61 of 110 tumors, 55.45%), but no methylation was found in normal lung tissues. Re-expression of CDX2 suppressed lung cancer cell proliferation and blocked cells in G1 phase. β-catenin/TCF activity and downstream genes expression were inhibited by re-expression of CDX2, and increased by depletion of CDX2. In conclusion, CDX2 is frequently methylated in lung cancer, and expression of CDX2 is regulated by promoter region hypermethylation. CDX2 may serve as a tumor suppressor in lung cancer and inhibits lung cancer cell proliferation by suppressing Wnt signaling.

Original languageEnglish (US)
Pages (from-to)1152-1157
Number of pages6
JournalCancer Biology and Therapy
Volume13
Issue number12
DOIs
StatePublished - Oct 2012

Fingerprint

Homeobox Genes
Lung Neoplasms
Methylation
Genetic Promoter Regions
decitabine
Transcription Factors
Cell Proliferation
Cell Line
Catenins
Neoplasms
Polymerase Chain Reaction
Gene Regulatory Networks
G1 Phase

Keywords

  • 5-aza-2'-deoxycytidine
  • CDX2
  • DNA methylation
  • Epigenetics
  • Lung cancer
  • Wnt signaling pathway

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. / Liu, Xuefeng; Zhang, Xiaomei; Zhan, Qimin; Brock, Malcolm V; Herman, James G.; Guo, Mingzhou.

In: Cancer Biology and Therapy, Vol. 13, No. 12, 10.2012, p. 1152-1157.

Research output: Contribution to journalArticle

Liu, Xuefeng ; Zhang, Xiaomei ; Zhan, Qimin ; Brock, Malcolm V ; Herman, James G. ; Guo, Mingzhou. / CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. In: Cancer Biology and Therapy. 2012 ; Vol. 13, No. 12. pp. 1152-1157.
@article{7fd8c462171f4f29b085844f72902f1d,
title = "CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer",
abstract = "Aberrant promoter region hypermethylation of upstream transcription factors may be responsible for silencing entire anti-neoplastic gene networks. In this study, we explored whether transcription factor coding gene, caudal-related homeobox 2 (CDX2), is silenced by promoter hypermethylation in lung cancer, and examined its potential tumor-suppressive functions. Semi-quantitative RT-PCR showed that four of six lung cancer cell lines exhibited no or weak CDX2 expression. Expression of CDX2 was correlated to CDX2 promoter region methylation status, as determined by methylation-specific PCR (MSP) and bisulfite sequencing. Restoration of CDX2 expression was induced by treatment with demethylating drug 5-aza-2′-deoxycytidine (5-AZA) in lung cancer cell lines. Methylation of CDX2 was common in human primary lung cancer (61 of 110 tumors, 55.45{\%}), but no methylation was found in normal lung tissues. Re-expression of CDX2 suppressed lung cancer cell proliferation and blocked cells in G1 phase. β-catenin/TCF activity and downstream genes expression were inhibited by re-expression of CDX2, and increased by depletion of CDX2. In conclusion, CDX2 is frequently methylated in lung cancer, and expression of CDX2 is regulated by promoter region hypermethylation. CDX2 may serve as a tumor suppressor in lung cancer and inhibits lung cancer cell proliferation by suppressing Wnt signaling.",
keywords = "5-aza-2'-deoxycytidine, CDX2, DNA methylation, Epigenetics, Lung cancer, Wnt signaling pathway",
author = "Xuefeng Liu and Xiaomei Zhang and Qimin Zhan and Brock, {Malcolm V} and Herman, {James G.} and Mingzhou Guo",
year = "2012",
month = "10",
doi = "10.4161/cbt.21344",
language = "English (US)",
volume = "13",
pages = "1152--1157",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "12",

}

TY - JOUR

T1 - CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer

AU - Liu, Xuefeng

AU - Zhang, Xiaomei

AU - Zhan, Qimin

AU - Brock, Malcolm V

AU - Herman, James G.

AU - Guo, Mingzhou

PY - 2012/10

Y1 - 2012/10

N2 - Aberrant promoter region hypermethylation of upstream transcription factors may be responsible for silencing entire anti-neoplastic gene networks. In this study, we explored whether transcription factor coding gene, caudal-related homeobox 2 (CDX2), is silenced by promoter hypermethylation in lung cancer, and examined its potential tumor-suppressive functions. Semi-quantitative RT-PCR showed that four of six lung cancer cell lines exhibited no or weak CDX2 expression. Expression of CDX2 was correlated to CDX2 promoter region methylation status, as determined by methylation-specific PCR (MSP) and bisulfite sequencing. Restoration of CDX2 expression was induced by treatment with demethylating drug 5-aza-2′-deoxycytidine (5-AZA) in lung cancer cell lines. Methylation of CDX2 was common in human primary lung cancer (61 of 110 tumors, 55.45%), but no methylation was found in normal lung tissues. Re-expression of CDX2 suppressed lung cancer cell proliferation and blocked cells in G1 phase. β-catenin/TCF activity and downstream genes expression were inhibited by re-expression of CDX2, and increased by depletion of CDX2. In conclusion, CDX2 is frequently methylated in lung cancer, and expression of CDX2 is regulated by promoter region hypermethylation. CDX2 may serve as a tumor suppressor in lung cancer and inhibits lung cancer cell proliferation by suppressing Wnt signaling.

AB - Aberrant promoter region hypermethylation of upstream transcription factors may be responsible for silencing entire anti-neoplastic gene networks. In this study, we explored whether transcription factor coding gene, caudal-related homeobox 2 (CDX2), is silenced by promoter hypermethylation in lung cancer, and examined its potential tumor-suppressive functions. Semi-quantitative RT-PCR showed that four of six lung cancer cell lines exhibited no or weak CDX2 expression. Expression of CDX2 was correlated to CDX2 promoter region methylation status, as determined by methylation-specific PCR (MSP) and bisulfite sequencing. Restoration of CDX2 expression was induced by treatment with demethylating drug 5-aza-2′-deoxycytidine (5-AZA) in lung cancer cell lines. Methylation of CDX2 was common in human primary lung cancer (61 of 110 tumors, 55.45%), but no methylation was found in normal lung tissues. Re-expression of CDX2 suppressed lung cancer cell proliferation and blocked cells in G1 phase. β-catenin/TCF activity and downstream genes expression were inhibited by re-expression of CDX2, and increased by depletion of CDX2. In conclusion, CDX2 is frequently methylated in lung cancer, and expression of CDX2 is regulated by promoter region hypermethylation. CDX2 may serve as a tumor suppressor in lung cancer and inhibits lung cancer cell proliferation by suppressing Wnt signaling.

KW - 5-aza-2'-deoxycytidine

KW - CDX2

KW - DNA methylation

KW - Epigenetics

KW - Lung cancer

KW - Wnt signaling pathway

UR - http://www.scopus.com/inward/record.url?scp=84867126262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867126262&partnerID=8YFLogxK

U2 - 10.4161/cbt.21344

DO - 10.4161/cbt.21344

M3 - Article

C2 - 22892849

AN - SCOPUS:84867126262

VL - 13

SP - 1152

EP - 1157

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 12

ER -